Montara Therapeutics Receives Research Grant from The Michael J. Fox Foundation to Advance Parkinson’s Disease ProgramBuilding on a prior MJFF-funded collaboration targeting LRRK2, Montara's BrainOnly™ platform now targets the mTOR pathway — exploring a class of drugs with longstanding scientific interest but a history of safety challenges.
Montara Therapeutics to Develop Novel Treatments Using the BrainOnly™ Platform with Grant from The Michael J. Fox FoundationSAN FRANCISCO, May 21, 2025 (GLOBE NEWSWIRE) -- Montara Therapeutics, a biotech company pioneering brain-selective therapies for central nervous system (CNS) diseases, today announced it has received a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), in addition to joining MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE) program, which supports the development of new therapies that target LRRK2 while also advancing progress toward new LRRK2-relevant clinical biomarkers.
Montara Therapeutics Closes $8 Million Seed Round Led by SV Health Investors’ Dementia Discovery Fund and Two Bear Capital to Develop Safer, More Effective Neuroscience Drugs Using a Novel Brain-Only Pharmacology ApproachSAN FRANCISCO, July 30, 2024 (GLOBE NEWSWIRE) -- Montara Therapeutics, Inc. (‘Montara’), a therapeutics company aiming to revolutionize the discovery and development of brain-targeting drugs, announced today the closing of an oversubscribed $8 million seed financing led by SV Health Investors’ Dementia Discovery Fund and co-lead Two Bear Capital. Dolby Family Ventures and KdT Ventures also participated in the round.
